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Abstract
Background: Primary leiomyosarcoma of the seminal vesicle is exceedingly rare.
Case Presentation: We report a case of a 59-year-old man with tumour detected by rectal symptoms and
ultrasonography. Computed tomography and magnetic resonance imaging suggested an origin in the right
seminal vesicle. Transperineal biopsy of the tumour revealed leiomyosarcoma. A radical vesiculo-prostactectomy
with bilateral pelvic lymphadenectomy was performed. Pathological examination showed a grade 2
leiomyosarcoma of the seminal vesicle. The patient received adjuvant radiotherapy. He developed distant
metastases 29 months after diagnosis, and received chemotherapy. Metastatic disease was controlled by second-
line gemcitabine-docetaxel combination. Fifty-one months after diagnosis of the primary tumour, and 22 months
after the first metastases, the patient is alive with excellent performance status, and multiple asymptomatic stable
lung and liver lesions.
Conclusions: We report the eighth case of primary leiomyosarcoma of the seminal vesicle and the first one with a
so long follow-up.
Keywords: leiomyosarcoma, seminal vesicle
Background
Less than 5% of soft tissue sarcomas (STS) arise from
the genitourinary tract. Leiomyosarcomas of the seminal
vesicle are exceedingly rare. To our knowledge, only
seven cases have been reported to date in the English
literature and all with a short follow-up [1-6]. Diagnosis,
initially described as difficult because of invaded sur-
rounding structures, which obscure the actual place of
origin, is being facilitated by modern imaging techniques
such as computed tomography and magnetic resonance
imaging. Data on optimal treatment are limited, but
radical surgery seems essential. The role of adjuvant
chemotherapy and radiotherapy remains unclear. Here,
we report an additional case of primary leiomyosarcoma
of the seminal vesicle with a long follow-up of more
than 4 years, and review the literature.
Case presentation
The patient was a 59-year old man, Caucasian type,
without any specific medical personal or familial history.
In October 2006, he underwent a pelvic ultrasonography
(US) because he presented a “pressure sensation” in the
rectum and rectal imperiosity for four weeks. Physical
examination revealed no additional symptom, except the
rectal examination that detected a 4-cm hard pre-rectal
mass filling the right side of the pelvis. The WHO per-
formance status was equal to 0. Ultrasonography (US)
discovered a tumour located at the right side of the pel-
vis. Serum prostate-specific antigen levels were normal.
The patient was thus referred to hospital.
Computed tomography (CT) of abdomen and pelvis
revealed an 8-cm heterogeneous tumour predominantly
located on the right side of the pelvis likely arising from
the right seminal vesicle, reaching the median line and
adherenting to the posterior bladder wall and the ante-
rior rectal wall. Due to the rectal clinical symptoms and
the suspicion of rectal adherence on CT scan, the core
needle biopsy was CT-guided transperineal rather than
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transrectal. Pathological analysis revealed a well-differen-
tiated leiomyosarcoma. Pelvic magnetic resonance ima-
ging (MRI) confirmed the presence of a mass centred
on the right seminal vesicle, causing mass effect on the
prostate and left seminal vesicle, without a cleavage
plane with the right prostate and the right obturator
muscle, suggesting invasion (Figure 1). Otherwise, MRI
clearly showed fat interface between the mass, the pos-
terior bladder wall and the anterior rectal wall without
any sign of involvement. Complete clinical and radiolo-
gical screening did not detect any lymphadenopathy or
distant metastasis. Based on these data, the tumor was
considered completely resectable, and surgery was
decided.
Before surgery, the examination under general
anesthesia revealed that the mass was difficult to mobi-
lize. The treatment consisted of a radical vesiculo-pros-
tatectomy with limited (ilio-obturator and hypogastric)
bilateral pelvic lymphadenectomy in January 2007, asso-
ciated with resection of the internal obturator muscle.
No anterior rectal resection was necessary. Excision was
macroscopically complete. The post-operative course
was uneventful. The pathological macroscopic examina-
tion of the surgical resection specimen showed a small
prostate (4.5 × 4 × 3 cm) and an 8 × 8 × 6.5 cm well-
limited hard white-tan mass, centred on the right semi-
nal vesicle, tangent to the prostate base, pushing the vas
deferens, the prostate and the left seminal vesicle. On
cut section the mass showed a grey-white whorled
appearance with foci of necrosis. Microscopic analysis
(Figure 2A) confirmed the previous diagnosis by show-
ing intersecting fascicles of atypical spindle cells with
elongated blunt-ended nuclei and eosinophilic cytoplasm
very reminiscent of smooth muscle differentiation.
Immunohistochemical analysis showed strong positive
staining of the tumour cells for smooth-muscle actin
and H-caldesmone (Figure 2B-D), and negative staining
for pan-cytokeratin AE1/AE3, CD117. The mitotic rate
averaged ten mitoses per ten high-power fields. Necrosis
was present on less than 50% of the tumour surface.
The tumour seemed developed within the wall of the
right seminal vesicle. It was a well-limited and pseudo-
wrapped with limited surgical margins, sometimes infer-
ior to 1 mm. The retained diagnosis was moderately dif-
ferentiated (FNCLCC grade 2) leiomyosarcoma of the
right seminal vesicle. The fourteen removed pelvic
lymph nodes were free of tumour. Moreover, an asso-
ciated small (4 × 4 × 2 mm) prostatic adenocarcinoma
was fortuitously discovered on the left apex of the
gland, Gleason 6 (3+3), without any macro- and micro-
scopical connection with the sarcoma. After surgery and
because of closed margins for the leiomyosarcoma, the
patient received adjuvant pelvic external beam radiation
therapy achieved in April 2007 (56 Gy./31 fractions). No
adjuvant chemotherapy was delivered. The patient was
then regularly monitored at the clinical and radiological
levels.
In April 2009, 29 months after diagnosis, he developed
two subcutaneous nodules on the scalp. Surgical
removal and pathological analysis confirmed the diagno-
sis of distant recurrences of leiomyosarcoma. At the
same time, CT and TEP scans detected the presence of
multiple asymptomatic liver and lung metastases.
Performance status was excellent (WHO 0). First-line
chemotherapy consisted of six cycles combining doxoru-
bicin and ifosfamide, but metastases progressed (Octo-
ber 2009), and the patient was referred to our
Figure 1 Magnetic resonance imaging of the pelvis. A/Coronal
T2-weighted MRI showing an heterogeneous mass lesion in the
region of right seminal vesicle, causing inferiorly and to the left
displacement of the prostate (white arrow) and of the left seminal
vesicle which appears normal (star). B/Axial contrast-enhanced T1-
weighted MRI showing distinct margins between the mass and
both the posterior wall of the bladder (black arrow) and the anterior
wall of the rectum (white arrow). Figure 2 Well-differentiated leiomyosarcoma. A/H&E staining
showing intersecting fascicles of moderately atypical elongated cells
with abundant eosinophilic cytoplasm. Mitoses (black arrows) are
seen (original magnification X 200). B-D/Immunohistochemical
analysis showing that tumour cells strongly express smooth-muscle
actin (B, X 200) and H-caldesmone (C, X 200). 15% of the cells are
stained by Ki-67 proliferative marker (D, X 200).
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institution for second-line chemotherapy. We delivered
a gemcitabine-docetaxel combination. After three cycles,
CT scan showed stable lung and liver lesions, whose
size decreased after the sixth cycle, then after the ninth
cycle, with a 30% response when compared with Octo-
ber 2009 (Figure 3). Treatment was then interrupted,
and the patient regularly followed. A last visit, in Febru-
ary 2011, 51 months after diagnosis of the primary
tumour, and 22 months after the first metastasis, the
patient is alive with excellent performance status, with-
out any symptom, and with multiple stable lung and
liver lesions.
Discussion
Primary malignant tumours of the seminal vesicles are
very rare. Among them, carcinomas are much more fre-
quent than sarcomas [7]. Primary leiomyosarcoma of
the seminal vesicle is extremely rare with to our knowl-
edge only seven cases reported in the English literature.
Our case represents the eighth patient, and the first one
with a follow-up superior to 30 months.
All cases are summarized in Table 1. The median age
of patients at the time of diagnosis is 59,5 years (range,
37 to 68). No specific risk factor has been identified.
Clinical detection of seminal vesicle tumours is difficult.
Depending on the size and extension of the tumour,
patients are either asymptomatic with discovery of the
lesion by palpation on routine rectal examination (3
cases), or present non-specific urinary and/or rectal
symptoms (5 cases). Of note, no case with hemospermia,
hematuria or anejaculation has been reported.
Radiological imaging is useful for the diagnosis and
staging of seminal vesicle tumours, notably to locate the
initial site of tumour development. Indeed, these
tumours tend to invade neighbouring structures in the
retrovesical space, causing difficulty in determining the
organ of origin, and leading to radical resection of sev-
eral major organs. Generally the first exam is US either
transrectal or transabdominal. More frequently, pelvic
CT and above all MRI allow the localisation of the
tumour in the seminal vesicle and a better appreciation
of the locoregional extension before surgery. In our
case, and as previously reported [6], MRI findings
strongly suggested a tumour origin in the right seminal
vesicle, followed by extension to adjacent organs (pros-
tate, internal obturator muscle).
Sarcoma diagnosis is provided by pathological analysis
of the tumour sample, either after needle biopsy (5 cases
including ours), or after surgical resection (1 case). In all
cases, definitive diagnosis was done by histological exam-
ination of the resected tumour. In our case, the finding of
a small adenocarcinoma raised the possibility of a sarco-
matoid carcinoma but the macroscopical presentation of
a clearly extraprostatic tumour, the absence of any con-
nection between the two proliferations, and negativity of
epithelial markers by immunochemistry did not favour
this diagnosis. Differential diagnosis also concerns lei-
moyosarcoma arising from adjacent organs (prostate,
bladder, rectum) and secondarily invading the seminal
vesicle. But today, thanks to the advent of modern ima-
ging tools, the organ of origin can be documented in
most of cases by looking at the epicentre of the mass and
the pattern of displacement of adjacent organs [6].
The prognosis of leiomyosarcoma of the seminal vesi-
cle is poor, and more unfavourable than other urological
sarcoma arising from the bladder or paratesticular site
[4]. This is partly due to the uncommon form of presen-
tation, delay in diagnosis, and difficulty in complete sur-
gical excision. This overall poor prognosis is
demonstrated in Table 1. Indeed, the median follow-up
of the 8 cases is short (22 months; range, 6 to 51), and
of note, the 3 patients with a follow-up superior to 24
months all experienced metastatic relapse at 24, 29, and
29 months. The 5 other patients, alive without any
relapse, present a median follow-up of only 14 months
(range, 6 to 24). Our case represents the one with the
longest follow-up (51 months). Obviously, the small
number of cases precludes any prognostic analysis.
Metastatic relapses occurred in the 3 patients with
microscopically incomplete resection (2 cases) and/or
high grade (2 cases) and/or tumour size superior to 5
cm (2 cases), suggesting that those sarcomas share prog-
nostic features with STS arising from other sites.
Figure 3 Response of lung metastases to gemcitabine-
docetaxel chemotherapy. Chest CT-scan performed in October
2009 (A-B) and in August 2010 (C-D) showing partial response of
lung metastases (arrows) after 9 cycles of second-line gemcitabine-
docetaxel combination.
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Data on optimal treatment are obviously limited. The
main treatment is surgery, which consisted of a cysto-
prostatectomy with a pelvic lymphadenectomy in all
reported cases, except ours where vesiculo-prostatect-
omy was done without cystectomy and without any
local relapse during the follow-up. As usually in STS,
only complete resection of the tumour offers a chance
for a cure. In the literature, the margins were positive in
only 2 cases. In our case the margins were very close,
less than 1 mm, justifying the use of adjuvant radiation
therapy. The role of adjuvant radiation therapy in visc-
eral STS is not established [8], and only two out of 8
reported cases, including ours with very close margins,
received such treatment. Of note, none of the 8 patients,
including ours treated without cystectomy, experienced
any local relapse during the available follow-up. Regard-
ing adjuvant chemotherapy, its role in STS remains
unclear [9], and only one patient received adjuvant com-
bination of doxorubicin, ifosfamide and dacarbazine
(MAID). Anthracycline-based chemotherapy was offered
to the 3 patients at the time of metastatic relapse, but
the response is documented in our case only. Our
patient’s disease progressed after 6 doxorubicin-ifosfa-
mide cycles, but responded to second-line chemotherapy
based on gemcitabine and docetaxel, as observed with
leiomyosarcomas arising from other sites [10].
Conclusions
We report the eighth case of primary leiomyosarcoma of
the seminal vesicle with the longest follow-up. As these
tumours are exceptional and information about standard
treatment is lacking, we think that case reports such as
this one may serve as the only reference for clinicians
taking care of these patients. Radical surgical excision is
the best chance for cure, but the need for cystectomy
must be discussed. Furthermore, like leiomyosarcomas
from other sites, a multimodality treatment deserves to
be discussed and systemic therapy to be improved given
the metastatic risk and overall poor prognosis. In this
context, the gemcitabine-docetaxel combination is likely
so efficient than in other locations.
Consent
Written informed consent was obtained from the patient
(February 2011) for publication of this case report and
any accompanying images. A copy of the written con-
sent is available for review by the Editor-in-Chief of this
journal.
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[5] 60 none (RE) yes surgery R0 3,5 cm intermediate no 14 months: no relapse, alive
[4] NA none (RE) NA surgery R1 NA high no 24 months: no relapse, alive
[4] NA none (RE) NA surgery R1 NA high no 29 months: metastasis (lung),
alive with disease
(doxorubicin)
[2] 68 rectal and
pain
yes surgery R0 10 cm high no 13 months: no relapse, alive
[3] 64 urinary no surgery R0 8 cm high no 24 months: metastasis




yes surgery NA NA NA no 6 months: no relapse, alive
[1] 37 urinary
and rectal
yes surgery NA 15 cm intermediate CT (MAID)
and RT
20 months: no relapse, alive
Our case 59 rectal yes surgery R1 8 cm intermediate RT 29 months: metastases (sub-
cutaneous, lung, liver: MAI);
51 months: alive with disease
(gemcitabine-docetaxel)
RE, rectal examination; NA, not available; CT, chemotherapy; MAID, mesna + doxorubicin + ifosfamide + dacarbazine; RT, radiation therapy.
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